



Comprehensive Heart Protection

In Dyslipidemia with **High CV Risk**

^{Rx} Diet, Exercise &

Roswow™-A ¹⁰/₂₀

Rosuvastatin 10/20 mg + Aspirin 75 mg Capsules



In Dyslipidemia with **ASCVD**

^{Rx} Diet, Exercise &

Roswow™-CV ¹⁰/₂₀

Rosuvastatin 10/20 mg + Clopidogrel 75 mg Capsules



In Post Event and High CV risk

^{Rx} Diet, Exercise &

Roswow™-Gold ¹⁰/₂₀

Rosuvastatin 10/20 mg + Aspirin 75 mg + Clopidogrel 75 mg Capsules



In Dyslipidemia with High CV Risk

^R Diet, Exercise &

Rosw^{ow}-A 10/20
Rosuvastatin 10/20 mg + Aspirin 75 mg Capsules

In Dyslipidemia with ASCVD

^R Diet, Exercise &

Rosw^{ow}-CV 10/20
Rosuvastatin 10/20 mg + Clopidogrel 75 mg Capsules

In Post Event and High CV risk

^R Diet, Exercise &

Rosw^{ow}-Gold 10/20
Rosuvastatin 10/20 mg + Aspirin 75 mg + Clopidogrel 75 mg Capsules

Background

- India carries a high burden of Acute Coronary Syndrome (ACS), with myocardial infarction (MI) and unstable angina being the most common presentations.
- Post-ACS patients have a significantly higher risk of recurrent coronary events than those with stable coronary disease, driven by dyslipidemia and progressive atherosclerosis.
- CREATE registry (n=20,937) suggested a higher prevalence of STEMI among Indian ACS patients compared to developed countries.
- Dual antiplatelet therapy (aspirin + clopidogrel) combined with rosuvastatin effectively lowers the risk of recurrent ischemic events without significantly increasing major bleeding.

Product Description

- ROSWOW A / CV/ GOLD** is a rational fixed-dose combination designed for Comprehensive protection against both lipid & thrombotic risks.

Available strengths

- ROSWOW-A 10/20:** Rosuvastatin 10 mg / 20 mg + Aspirin 75 mg (Capsules)
- ROSWOW-CV 10/20:** Rosuvastatin 10 mg / 20 mg + Clopidogrel 75 mg (Capsules)
- ROSWOW-GOLD 10/20:** Rosuvastatin 10 mg / 20 mg + Aspirin 75 mg + Clopidogrel 75 mg (Capsules)

Indication

ROSWOW-A / CV/ GOLD is indicated as an adjunct to diet & exercise

- In Dyslipidemia with High CV Risk
- In Dyslipidemia With ASCVD
- In Post Event and High CV Risk

Mechanism of Action

- Rosuvastatin: Potent HMG-CoA reductase inhibitor, lowers LDL-C, stabilizes plaques, and reduces vascular inflammation.
- Aspirin: Irreversibly inhibits COX-1, reducing thromboxane A2 and preventing platelet aggregation.
- Clopidogrel: Blocks the P2Y12 ADP receptor on platelets, inhibiting platelet activation and thrombus formation.

Dosage & Administration

- One capsule daily (OD) or as prescribed by the Doctor

STEMI: ST-segment Elevation Myocardial Infarction
DAPT: Dual Antiplatelet Therapy

References:

- Lancet. 2008 Apr 26;371(9622):1435-42
- Clinics (Sao Paulo). 2023 Jan-Dec; 78: 100171.



Corp. & Regd. Office:

1009-1010, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019 Tel.: 011-47589500-51 (50 lines)

Web: www.medicamen.com/lifesciences | E-mail: info@medicamenlifesciences.com

I am:.....
Call me on:.....
Mail me at:.....

2025 All rights reserved, Medicamen Lifesciences Pvt Ltd